BCMAS Exam Study Questions with
Complete Solutions 2025/2026
A medical director has recently completed the final draft for a poster
she is presenting at the upcoming American Heart Association (AHA)
meeting. In order for the poster to be presented, she will need to work
pg. 1
,with which of the following internal functions for approval of the poster
and its contents? (Select all that apply)
a.clinical
b. Commercial
c. Legal
d. Regulatory - ANSWER -a.clinical
c. Legal
d. Regulatory
The stage at which experiments are conducted on humans is during...
a. Labeling process
b. Pre-clinical trials
c. Discovery phase
d. Clinical trialals - ANSWER -d. Clinical trials
Which of the following is NOT a driver of growth for the pharmaceutical
industry?
a. Aging population
b. Increased income
c. The increase in chronic diseases
d. Shorter patent life - ANSWER -d. Shorter patent life
pg. 2
,An API is produced by companies that:
a. sell off-patented drugs
b. design and sell patented drugs
c. produce raw materials
d. produce drugs under license from other companies - ANSWER -c.
produce raw materials
International regulatory bodies include the
a. FDA, DoJ, WHO
b. MHRA and WHO
c. DoJ and OPDP
d. OIG and FDA - ANSWER -b. MHRA and WHO
The sequence best describing the supply chain process is:
a. Raw material --> distributors --> manufacturing units
b. Raw material --> regional warehouses --> central warehouse
c. Raw material --> manufacturing units --> distributors
d. Raw material --> distributors --> central warehouses - ANSWER -c.
Raw material --> manufacturing units --> distributors
A scientist working at a pharmaceutical company discovers a currently
commercialized Beta blocker which fits well into the company's current
pg. 3
, cardiovascular product portfolio. To which team should she
communicate this information?
a. Legal
b. The business development team
c. The R&D team
d. Medical affairs team - ANSWER -b. The business development team
HEOR is used to demonstrate
a. The legal benefits of the new drug
b. The effectiveness of the new drug
c. The risks of a new drug
d. The cost-benefit analysis of a new drug - ANSWER -d. The cost-
benefit analysis of a new drug
A company filing an NDA is the function of
a. Legal
b. Regulatory
c. Compliance
d. Commercial - ANSWER -b. Regulatory
Labeling for the prescribing information takes place...
a. During post-market research
b. After an NDA is approved
pg. 4
Complete Solutions 2025/2026
A medical director has recently completed the final draft for a poster
she is presenting at the upcoming American Heart Association (AHA)
meeting. In order for the poster to be presented, she will need to work
pg. 1
,with which of the following internal functions for approval of the poster
and its contents? (Select all that apply)
a.clinical
b. Commercial
c. Legal
d. Regulatory - ANSWER -a.clinical
c. Legal
d. Regulatory
The stage at which experiments are conducted on humans is during...
a. Labeling process
b. Pre-clinical trials
c. Discovery phase
d. Clinical trialals - ANSWER -d. Clinical trials
Which of the following is NOT a driver of growth for the pharmaceutical
industry?
a. Aging population
b. Increased income
c. The increase in chronic diseases
d. Shorter patent life - ANSWER -d. Shorter patent life
pg. 2
,An API is produced by companies that:
a. sell off-patented drugs
b. design and sell patented drugs
c. produce raw materials
d. produce drugs under license from other companies - ANSWER -c.
produce raw materials
International regulatory bodies include the
a. FDA, DoJ, WHO
b. MHRA and WHO
c. DoJ and OPDP
d. OIG and FDA - ANSWER -b. MHRA and WHO
The sequence best describing the supply chain process is:
a. Raw material --> distributors --> manufacturing units
b. Raw material --> regional warehouses --> central warehouse
c. Raw material --> manufacturing units --> distributors
d. Raw material --> distributors --> central warehouses - ANSWER -c.
Raw material --> manufacturing units --> distributors
A scientist working at a pharmaceutical company discovers a currently
commercialized Beta blocker which fits well into the company's current
pg. 3
, cardiovascular product portfolio. To which team should she
communicate this information?
a. Legal
b. The business development team
c. The R&D team
d. Medical affairs team - ANSWER -b. The business development team
HEOR is used to demonstrate
a. The legal benefits of the new drug
b. The effectiveness of the new drug
c. The risks of a new drug
d. The cost-benefit analysis of a new drug - ANSWER -d. The cost-
benefit analysis of a new drug
A company filing an NDA is the function of
a. Legal
b. Regulatory
c. Compliance
d. Commercial - ANSWER -b. Regulatory
Labeling for the prescribing information takes place...
a. During post-market research
b. After an NDA is approved
pg. 4
